These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 19752302)

  • 1. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.
    Jacob A; Matiello M; Weinshenker BG; Wingerchuk DM; Lucchinetti C; Shuster E; Carter J; Keegan BM; Kantarci OH; Pittock SJ
    Arch Neurol; 2009 Sep; 66(9):1128-33. PubMed ID: 19752302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China.
    Chen H; Zhang Y; Shi Z; Feng H; Yao S; Xie J; Zhou H
    Clin Neuropharmacol; 2016; 39(2):81-7. PubMed ID: 26818042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
    Huh SY; Kim SH; Hyun JW; Joung AR; Park MS; Kim BJ; Kim HJ
    JAMA Neurol; 2014 Nov; 71(11):1372-8. PubMed ID: 25199960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
    Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
    Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China.
    Huang Q; Wang J; Zhou Y; Yang H; Wang Z; Yan Z; Long Y; Yin J; Feng H; Li C; Lu Z; Hu X; Qiu W
    Front Immunol; 2018; 9():2066. PubMed ID: 30258442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
    Kitley J; Elsone L; George J; Waters P; Woodhall M; Vincent A; Jacob A; Leite MI; Palace J
    J Neurol Neurosurg Psychiatry; 2013 Aug; 84(8):918-21. PubMed ID: 23467418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
    Chen H; Qiu W; Zhang Q; Wang J; Shi Z; Liu J; Lian Z; Feng H; Miao X; Zhou H
    Eur J Neurol; 2017 Jan; 24(1):219-226. PubMed ID: 27783452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
    JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.
    Mealy MA; Wingerchuk DM; Palace J; Greenberg BM; Levy M
    JAMA Neurol; 2014 Mar; 71(3):324-30. PubMed ID: 24445513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.
    Ringelstein M; Ayzenberg I; Harmel J; Lauenstein AS; Lensch E; Stögbauer F; Hellwig K; Ellrichmann G; Stettner M; Chan A; Hartung HP; Kieseier B; Gold R; Aktas O; Kleiter I
    JAMA Neurol; 2015 Jul; 72(7):756-63. PubMed ID: 25985228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
    Costanzi C; Matiello M; Lucchinetti CF; Weinshenker BG; Pittock SJ; Mandrekar J; Thapa P; McKeon A
    Neurology; 2011 Aug; 77(7):659-66. PubMed ID: 21813788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.
    Hinson SR; McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Pittock SJ
    Arch Neurol; 2009 Sep; 66(9):1164-7. PubMed ID: 19752309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
    Montcuquet A; Collongues N; Papeix C; Zephir H; Audoin B; Laplaud D; Bourre B; Brochet B; Camdessanche JP; Labauge P; Moreau T; Brassat D; Stankoff B; de Seze J; Vukusic S; Marignier R;
    Mult Scler; 2017 Sep; 23(10):1377-1384. PubMed ID: 27885065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
    Viswanathan S; Wong AH; Quek AM; Yuki N
    J Neuroimmunol; 2015 May; 282():92-6. PubMed ID: 25903734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.
    Kunchok A; Malpas C; Nytrova P; Havrdova EK; Alroughani R; Terzi M; Yamout B; Hor JY; Karabudak R; Boz C; Ozakbas S; Olascoaga J; Simo M; Granella F; Patti F; McCombe P; Csepany T; Singhal B; Bergamaschi R; Fragoso Y; Al-Harbi T; Turkoglu R; Lechner-Scott J; Laureys G; Oreja-Guevara C; Pucci E; Sola P; Ferraro D; Altintas A; Soysal A; Vucic S; Grand'Maison F; Izquierdo G; Eichau S; Lugaresi A; Onofrj M; Trojano M; Marriott M; Butzkueven H; Kister I; Kalincik T
    Mult Scler Relat Disord; 2020 Feb; 38():101868. PubMed ID: 31877445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study.
    Jiao Y; Cui L; Zhang W; Zhang C; Zhang Y; Zhang X; Jiao J
    BMC Neurol; 2018 Apr; 18(1):47. PubMed ID: 29688841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aquaporin-4 autoantibodies in a paraneoplastic context.
    Pittock SJ; Lennon VA
    Arch Neurol; 2008 May; 65(5):629-32. PubMed ID: 18474738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
    Jacob A; Weinshenker BG; Violich I; McLinskey N; Krupp L; Fox RJ; Wingerchuk DM; Boggild M; Constantinescu CS; Miller A; De Angelis T; Matiello M; Cree BA
    Arch Neurol; 2008 Nov; 65(11):1443-8. PubMed ID: 18779415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese.
    Chan KH; Ramsden DB; Yu YL; Kwok KH; Chu AC; Ho PW; Kwan JS; Lee R; Lim E; Kung MH; Ho SL
    Eur J Neurol; 2009 Mar; 16(3):310-6. PubMed ID: 19138340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.